Acepodia Announces FDA Clearance of IND for its NK Cell Therapy Drug Candidate ACE1702 to Treat Patients with HER2-expressing Solid Tumors

ACE1702 is a potential off-the-shelf cell therapy developed using Acepodia’s Antibody-Cell Conjugation technology

Acepodia, a biotechnology company developing cancer immunotherapy based on its novel ACC™ (Antibody Cell-Conjugation) technology platform, today announced it has received clearance of its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to initiate a Phase 1 clinical study of its natural killer (NK) cell therapy and lead drug candidate ACE1702 in patients with HER2-expressing solid tumors.

“The FDA’s clearance of our IND for ACE1702 is a major milestone for Acepodia that represents an important initial validation of our ACC™ platform, which can link any antibody, including those that have already proven effective in targeting tumors, to proprietary off-the-shelf natural killer cell line (oNK cells) without the need for genetic engineering,” said Sonny Hsiao, Ph.D., chief executive officer of Acepodia, and the inventor of ACC™ while at University of California, Berkeley. “This novel approach allows us to circumvent the complexity and the limitations associated with CAR-T and traditional NK based cell therapies.  ACC™ significantly improves manufacturing costs and has the potential to generate a cost-effective cancer treatment that can deliver increased benefit to patients. We look forward to advancing ACE1702 into its first clinical trial.”  

About ACE1702
ACE1702 is Acepodia’s lead clinical product candidate developed from the Company’s proprietary ACC™ platform. It targets human HER2-expressing solid tumors using anti-HER2 antibody conjugated oNK cells. ACE1702 has demonstrated enhanced tumor cell killing activities both in vitro and in vivo, while maintaining a favorable safety profile in GLP toxicology studies. In preclinical studies, ACE1702 has shown enhanced tumor-killing activities against HER2 IHC 1+, 2+ and 3+ human cancer cells.  

About Acepodia 
Acepodia is a privately held US-Taiwan biotechnology company committed to developing safe, effective, and affordable immunotherapeutic medicines targeting diseases with significant unmet medical needs, with a primary focus on oncology. Acepodia’s proprietary ACC™ (Antibody Cell-Conjugation) technology platform links tumor targeting antibodies to the surface of a novel and proprietary human NK cell line that have been specifically selected for their potent antitumor activity. The ACC technology can be seamlessly combined with currently available antibodies allowing for the rapid development of new targeted therapies in multiple indications, without the need for genetic engineering.

 

 

Jason Braco, Ph.D.
Account Executive

Acepodia Announces FDA Clearance of IND for its NK Cell Therapy Drug Candidate ACE1702 to Treat Patients with HER2-expressing Solid Tumors

Acepodia Announces FDA Clearance of IND for its NK Cell Therapy Drug Candidate ACE1702 to Treat Patients with HER2-expressing Solid Tumors

Cancer-News

1 week
19 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Up Next Autoplay
Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020
Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020
Category: News
2 Views
Cancer-News 15 hours
Alternative Pain-Control Strategy Reduces Need for Opioids in Patients with Head and Neck Cancer
Alternative Pain-Control Strategy Reduces Need for Opioids in Patients with Head and Neck Cancer
Category: Head and Neck Cancers
2 Views
Cancer-News 1 day
JAVELIN Study: How Does This Affect Clinicians?
JAVELIN Study: How Does This Affect Clinicians?
Category: Urology
2 Views
Cancer-News 2 days
What happened to patients with progression of disease?
What happened to patients with progression of disease?
Category: Urology
3 Views
Cancer-News 2 days
Phase III JAVELIN Study in Urothelial Cancer @tompowles1
Phase III JAVELIN Study in Urothelial Cancer @tompowles1
Category: Urology
12 Views
Cancer-News 2 days
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Category: Prostate Cancer
1 Views
Cancer-News 5 days
The Impact of Therapy with External-Beam Radiotherapy
The Impact of Therapy with External-Beam Radiotherapy
Category: Prostate Cancer
1 Views
Cancer-News 5 days
Is there a correlation between the target volume of radiation?
Is there a correlation between the target volume of radiation?
Category: Prostate Cancer
0 Views
Cancer-News 5 days
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
Category: Pancreatic Cancer
2 Views
Cancer-News 5 days
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Category: Prostate Cancer
11 Views
Cancer-News 5 days